Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK | Market Cap | 22.09B -27.8% |
| Revenue (ttm) | 9.24B +16,519.7% |
| Net Income | 6.40B |
| EPS | 89.42 |
| Shares Out | 70.66M |
| PE Ratio | 3.50 |
| Forward PE | 18.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 153,294 |
| Average Volume | 419,699 |
| Open | 310.50 |
| Previous Close | 312.60 |
| Day's Range | 301.10 - 312.80 |
| 52-Week Range | 233.50 - 556.00 |
| Beta | 0.56 |
| RSI | 46.40 |
| Earnings Date | May 7, 2026 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
Financial Performance
Financial StatementsNews
Zealand Pharma Launches DKK 1.3 Billion Buyback Plan, Stock Soars
Zealand Pharma Launches DKK 1.3 Billion Buyback Plan, Stock Soars
Zealand Pharma Earnings Call Transcript: Q1 2026
Q1 2026 saw major clinical and financial milestones, including strong phase II and III results for obesity candidates, robust cash reserves, and the launch of a $200 million share buyback. Strategic partnerships and a focus on R&D underpin a positive outlook for 2026.
Zealand Pharma Launches $200 Mln Share Buyback Program
(RTTNews) - Zealand Pharma A/S (ZEAL.CO, ZLDPF) announced on Thursday the launch of a share buyback program of up to $200 million, or DKK 1.3 billion.
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
Danish drug developer Zealand Pharma reported a smaller-than-expected first-quarter operating loss on Thursday, boosted by strong momentum in its obesity drug pipeline, and said it would l...
Zealand Pharma upgraded to Buy from Hold at SEB Equities
SEB Equities analyst Thomas Bowers upgraded Zealand Pharma (ZLDPF) to Buy from Hold with a DKK 475 price target
Zealand Pharma, Roche to advance petrelintide for weight management to Phase 3
Zealand Pharma A/S (ZLDPF) announced formal endorsement to advance petrelintide, an amylin analog for chronic weight management, into Phase 3 trials with its partner Roche (RHHBY). The initiation is p...
Zealand Pharma Announces Positive Topline Phase 3 Results For Weight-Loss Drug Survodutide
(RTTNews) - Zealand Pharma A/S (ZEAL.CO), a biotechnology company, announced on Tuesday that Boehringer Ingelheim reported promising topline results from the Phase 3 SYNCHRONIZE-1 trial for Survodutid...
Zealand Pharma appoints Eric Rojas as VP, head of IR
Zealand Pharma (ZLDPF) announced the appointment of Eric Rojas, Vice President, Investor Relations, effective April 15, 2026. Eric will report to Henriette Wennicke, CFO, and will be based in Massachu...
Zealand Pharma establishes U.S. research hub in Cambridge, Massachusetts
Zealand Pharma (ZLDPF) announced the establishment of a new research hub in Cambridge, Massachusetts, in the greater Boston area. The facility will serve as Zealand Pharma’s primary U.S. address and…
Zealand Pharma price target lowered to DKK 275 from DKK 450 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 275 from DKK 450 and keeps a Hold rating on the shares.
Zealand Pharma Transcript: Barclays 28th Annual Global Healthcare Conference
The discussion highlighted a robust pipeline targeting obesity and metabolic diseases, with Petrelintide showing strong efficacy and tolerability, and Survodutide poised for major phase III data this year. Strategic partnerships, financial strength, and upcoming clinical milestones position the company for significant growth.
Zealand Pharma price target lowered to DKK 460 from DKK 1,000 at JPMorgan
JPMorgan lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 460 from DKK 1,000 and keeps an Overweight rating on the shares.
Zealand Pharma downgraded to Neutral from Outperform at BNP Paribas
BNP Paribas downgraded Zealand Pharma (ZLDPF) to Neutral from Outperform with a DKK 275 price target
Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
Zealand Pharma obesity drug showed disappointing weight loss in a Phase 2 trial.
Zealand Pharma downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Zealand Pharma (ZLDPF) to Market Perform from Outperform without a price target The magnitude of weight loss disappointed in the Phase II ZUPREME-1 trial results, the analyst…
Zealand Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded Zealand Pharma (ZLDPF) to Neutral from Overweight. Zealand Pharma announced Phase 2b obesity data for petrelintide that showed weight loss of 9% placebo-adjusted at 42 wee...
Zealand Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Prakhar Agrawal downgraded Zealand Pharma (ZLDPF) to Neutral from Overweight.
Zealand Pharma downgraded to Hold from Buy at SEB Equities
SEB Equities downgraded Zealand Pharma (ZLDPF) to Hold from Buy with a DKK 380 price target
Zealand Pharma downgraded to Hold from Buy at Nordea
Nordea analyst Martin Brenoe downgraded Zealand Pharma (ZLDPF) to Hold from Buy.
Zealand Pharma slump wipes billions off its value after obesity drug data disappoints
Shares in Zealand Pharma tumbled more than 30% on Friday, putting the Danish biotech firm on track for its worst trading day on record, after mid-stage trial results for obesity drug petrelintide fe...
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Zealand Pharma Transcript: Study result
Petrelintide achieved sustained double-digit weight loss with a placebo-like safety profile in the phase II ZUPREME-1 trial, showing strong efficacy across doses and exceptional tolerability. These results support its advancement to phase III as a foundational therapy for chronic weight management.
Zealand Pharma Earnings Call Transcript: Q4 2025
2025 saw record revenue and profit, driven by the Roche partnership and strong R&D investment. Key obesity and metabolic assets, petrelintide and survodutide, are advancing with major clinical milestones expected in 2026, supported by a robust cash position.
Zealand Pharma announces topline results from ZP9830 trial
Zealand Pharma (ZLDPF) announced Phase 1a single ascending dose topline results for the company’s Kv1.3 channel blocker, ZP9830. The first-in-human, single-center, randomized, double-blind, placebo-co...
Zealand Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
Ambitious plans target obesity and metabolic diseases, with major clinical milestones for petrelintide and Survodutide expected in 2024. Strategic partnerships with Roche and Boehringer Ingelheim support a robust pipeline, aiming for five product launches in five years and significant investment in research.